{"contentid": 488230, "importid": NaN, "name": "Sanofi to build new Fluzone vaccine facility in Canada", "introduction": "With so much focus on products to fight the COVID-19 pandemic, French pharma major Sanofi has made clear it is not neglecting regular seasonal flu.", "content": "<p>With so much focus on products to fight the COVID-19 pandemic, French pharma major Sanofi (Euronext: SAN) has made clear it is not neglecting regular seasonal flu.</p>\n<p>Sanofi says that it is investing more than 600 million euros ($705 million) in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi&rsquo;s Fluzone High-Dose quadrivalent influenza vaccine, helping to increase supply availability in Canada, the USA and Europe.</p>\n<p>Sanofi expects this new facility to be operational in 2026, following design, construction, testing and qualification of the facility and equipment.</p>\n<p>&ldquo;As a leading vaccines company, we continuously look ahead to address the fast-growing demand for those influenza vaccines that have demonstrated clinical superiority against standard-dose vaccines. Fluzone High-Dose provides a long-term competitive advantage and this new investment will ensure more seniors around the world are better protected against influenza and its complications. In addition, it will be a key resource to assist against future pandemics,&rdquo; said Paul Hudson, chief executive of Sanofi, adding: &ldquo;We welcome the ongoing partnership with the Canadian authorities, who supported us to make today&rsquo;s great news a reality; this will make the country, which has a strong legacy in vaccines research and development, one of our key hubs in our effort to protect and improve human health across the globe.&rdquo;</p>\n<h2><strong>Shows Canada&rsquo;s ability to attract foreign investment</strong></h2>\n<p>Fran&ccedil;ois-Philippe Champagne, Minister of Innovation, Science and Industry, said<em>: </em>&ldquo;Today&rsquo;s announcement demonstrates Canada&rsquo;s ability to attract foreign investment and to develop facilities with made-in-Canada solutions. This once-in-a-generation investment shows our government&rsquo;s commitment to rebuilding Canada&rsquo;s domestic biomanufacturing sector, focusing on both short-term strategic solutions and a long\u00e2\u0080\u0091term vision. By investing in this project, our government is helping to keep expertise in Canada, creating and maintaining highly skilled jobs, and securing the health and safety of Canadians. By fostering an environment where companies can invest and grow, leading life sciences firms like Sanofi are increasingly looking to this country to establish their manufacturing facilities.&rdquo;</p>", "date": "2021-04-01 11:28:00", "meta_title": "Sanofi to build new Fluzone vaccine facility in Canada", "meta_keywords": "Sanofi, Fluzone, Vaccine facility, Canada, Investment", "meta_description": "Sanofi to build new Fluzone vaccine facility in Canada", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-01 11:25:24", "updated": "2021-04-01 11:32:06", "access": NaN, "url": "https://www.thepharmaletter.com/article/sanofi-to-build-new-fluzone-vaccine-facility-in-canada", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "sanofi_big.jpg", "image2id": "sanofi_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-virals, Vaccines", "topic_tag": "Production", "geography_tag": "Canada, France", "company_tag": "Sanofi", "drug_tag": "Fluzone", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-01 11:28:00"}